Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sobi has signed a distribution agreement with PharmaSwiss for Megace, Monopril, Cefzil and Duricef products.
Subscribe to our email newsletter
Sobi gained distribution rights in Ireland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden, Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal, and Luxembourg.
The distribution is expected to begin by the end of the first quarter 2013.
Sobi partner products vice president and head Anders Edvell said, "We are delighted to be able to provide patients and physicians with this portfolio of important treatment options, and to welcome PharmaSwiss as a new partner."
Megace, a progestogen hormone drug, is indicated for hormone-dependent neoplasms such as breast cancer, while Monopril is an angiotensin converting enzyme inhibitor for hypertension and congestive heart failure.
Cefzil is a cephalosporin antibiotic and Duricef, another cephalosporin antibiotic, is indicated for urinary tract infections, skin infections, pharyngitis and/or tonsillitis.